MetaVia Inc. to Present Key Findings on DA-1726 at ObesityWeek® 2026 in Washington, D.C.#United_States#Washington#MetaVia#DA-1726#ObesityWeek
MetaVia Inc. to Present Key Findings on DA-1726 at ObesityWeek® 2026 in Washington, D.C.
MetaVia Inc. unveils breakthrough insights on DA-1726, a dual agonist targeting cardiometabolic diseases, at ObesityWeek® 2026.
third-news.com
November 9, 2026 at 1:58 PM
MetaVia Inc. to Present Key Findings on DA-1726 at ObesityWeek® 2026 in Washington, D.C.#United_States#Washington#MetaVia#DA-1726#ObesityWeek
#MTVA MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
https://www.stocktitan.net/news/MTVA/meta-via-announces-poster-presentation-on-da-1726-at-obesity-week-4o9kuykgn7cw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-announces-poster-presentation-on-da-1726-at-obesity-week-4o9kuykgn7cw.html?utm_source=stocktitan-bluesky&utm_medium=social
MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 9, 2026 at 1:31 PM
#MTVA MetaVia Announces Poster Presentation on DA-1726 at ObesityWeek® 2026
https://www.stocktitan.net/news/MTVA/meta-via-announces-poster-presentation-on-da-1726-at-obesity-week-4o9kuykgn7cw.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-announces-poster-presentation-on-da-1726-at-obesity-week-4o9kuykgn7cw.html?utm_source=stocktitan-bluesky&utm_medium=social
MetaVia: DA-1726 Part 3B interim: liver fat −68% vs placebo, weight −13.5%; full Part 3A/3B data Q1 2027; cash $12.6M at June 30.
#$MTVA FAQ + PDF report: www.merlintrader.com/metavia-inc-...
#$MTVA FAQ + PDF report: www.merlintrader.com/metavia-inc-...
MTVA Stock: MetaVia News, DA-1726 & Funding
MetaVia stock news and analysis: DA-1726 obesity data, vanoglipel in liver disease, cash, financing obligations and the key development risks for MTVA holders.
www.merlintrader.com
November 5, 2026 at 7:29 PM
MetaVia: DA-1726 Part 3B interim: liver fat −68% vs placebo, weight −13.5%; full Part 3A/3B data Q1 2027; cash $12.6M at June 30.
#$MTVA FAQ + PDF report: www.merlintrader.com/metavia-inc-...
#$MTVA FAQ + PDF report: www.merlintrader.com/metavia-inc-...
👤 SiriusXM named Tubi CEO Anjali Sud as CEO starting Jan 1.
📊 Orthofix Medical released Q3 2026 financial results.
🧬 MetaVia presented DA-1726 data at ObesityWeek 2026.
🪙 Bitmine's ETH holdings reached 6.07 million tokens.
📊 Orthofix Medical released Q3 2026 financial results.
🧬 MetaVia presented DA-1726 data at ObesityWeek 2026.
🪙 Bitmine's ETH holdings reached 6.07 million tokens.
November 9, 2026 at 10:15 PM
👤 SiriusXM named Tubi CEO Anjali Sud as CEO starting Jan 1.
📊 Orthofix Medical released Q3 2026 financial results.
🧬 MetaVia presented DA-1726 data at ObesityWeek 2026.
🪙 Bitmine's ETH holdings reached 6.07 million tokens.
📊 Orthofix Medical released Q3 2026 financial results.
🧬 MetaVia presented DA-1726 data at ObesityWeek 2026.
🪙 Bitmine's ETH holdings reached 6.07 million tokens.
#MTVA MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
https://www.stocktitan.net/news/MTVA/meta-via-announces-statistically-significant-68-reduction-in-liver-3ba9oz0kwrbi.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-announces-statistically-significant-68-reduction-in-liver-3ba9oz0kwrbi.html?utm_source=stocktitan-bluesky&utm_medium=social
MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 5, 2026 at 1:55 PM
#MTVA MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data
https://www.stocktitan.net/news/MTVA/meta-via-announces-statistically-significant-68-reduction-in-liver-3ba9oz0kwrbi.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-announces-statistically-significant-68-reduction-in-liver-3ba9oz0kwrbi.html?utm_source=stocktitan-bluesky&utm_medium=social
#$MTVA weekly close $1.12 (-18.8% w/w), below SMA50 $1.52 / below SMA200 $1.68, RSI 32.2. Support $1.11, resistance $1.59. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/metavia-inc-...
New hub updated: www.merlintrader.com/metavia-inc-...
October 31, 2026 at 10:43 PM
#$MTVA weekly close $1.12 (-18.8% w/w), below SMA50 $1.52 / below SMA200 $1.68, RSI 32.2. Support $1.11, resistance $1.59. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/metavia-inc-...
New hub updated: www.merlintrader.com/metavia-inc-...
#$MTVA weekly close $1.12 (-18.8% w/w), below SMA50 $1.52 / below SMA200 $1.68, RSI 32.2. Support $1.11, resistance $1.59. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/metavia-inc-...
New hub updated: www.merlintrader.com/metavia-inc-...
October 31, 2026 at 10:43 PM
#$MTVA weekly close $1.12 (-18.8% w/w), below SMA50 $1.52 / below SMA200 $1.68, RSI 32.2. Support $1.11, resistance $1.59. Broad market sell-off Friday.
New hub updated: www.merlintrader.com/metavia-inc-...
New hub updated: www.merlintrader.com/metavia-inc-...
MetaVia to Showcase DA-1726 Phase 1 Clinical Data at 2026 Precision Liver Symposium#United_States#Denver#Clinical_Trials#MetaVia#DA-1726
MetaVia to Showcase DA-1726 Phase 1 Clinical Data at 2026 Precision Liver Symposium
MetaVia Inc. is set to present groundbreaking Phase 1 clinical trial results for DA-1726, a novel treatment targeting cardiometabolic diseases, at the upcoming Precision Liver Symposium.
third-news.com
October 28, 2026 at 12:53 PM
MetaVia to Showcase DA-1726 Phase 1 Clinical Data at 2026 Precision Liver Symposium#United_States#Denver#Clinical_Trials#MetaVia#DA-1726
$MTVA Oct 28, 2026: MetaVia's DA-1726 Phase 1 data have been accepted for an oral presentation at the Precision Liver Symposium on November 4.
https://www.merlintrader.com/metavia-inc-stock-hub/
https://www.merlintrader.com/metavia-inc-stock-hub/
MetaVia ($MTVA): DA-1726 Data And Funding
MetaVia faces longer DA-1726 obesity results, a limited cash horizon and material warrants. Dated clinical evidence, financing conditions and risks for $MTVA.
www.merlintrader.com
October 28, 2026 at 4:05 PM
$MTVA Oct 28, 2026: MetaVia's DA-1726 Phase 1 data have been accepted for an oral presentation at the Precision Liver Symposium on November 4.
https://www.merlintrader.com/metavia-inc-stock-hub/
https://www.merlintrader.com/metavia-inc-stock-hub/
$MTVA Oct 28, 2026: MetaVia's DA-1726 Phase 1 data have been accepted for an oral presentation at the Precision Liver Symposium on November 4.
https://www.merlintrader.com/metavia-inc-stock-hub/
https://www.merlintrader.com/metavia-inc-stock-hub/
MetaVia ($MTVA): DA-1726 Data And Funding
MetaVia faces longer DA-1726 obesity results, a limited cash horizon and material warrants. Dated clinical evidence, financing conditions and risks for $MTVA.
www.merlintrader.com
October 28, 2026 at 4:05 PM
$MTVA Oct 28, 2026: MetaVia's DA-1726 Phase 1 data have been accepted for an oral presentation at the Precision Liver Symposium on November 4.
https://www.merlintrader.com/metavia-inc-stock-hub/
https://www.merlintrader.com/metavia-inc-stock-hub/
$MTVA — Press Release
MetaVia Inc. (MTVA) furnished a Regulation FD press release announcing that an abstract highlighting Phase 1 clinical trial data for DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 and glucagon receptors, has been accepted for an oral pr...
🧵 continued ↓
MetaVia Inc. (MTVA) furnished a Regulation FD press release announcing that an abstract highlighting Phase 1 clinical trial data for DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 and glucagon receptors, has been accepted for an oral pr...
🧵 continued ↓
October 28, 2026 at 6:46 PM
$MTVA — Press Release
MetaVia Inc. (MTVA) furnished a Regulation FD press release announcing that an abstract highlighting Phase 1 clinical trial data for DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 and glucagon receptors, has been accepted for an oral pr...
🧵 continued ↓
MetaVia Inc. (MTVA) furnished a Regulation FD press release announcing that an abstract highlighting Phase 1 clinical trial data for DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 and glucagon receptors, has been accepted for an oral pr...
🧵 continued ↓
#MTVA MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
https://www.stocktitan.net/news/MTVA/meta-via-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-mtlixf7tl5hr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-mtlixf7tl5hr.html?utm_source=stocktitan-bluesky&utm_medium=social
MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
MetaVia (Nasdaq: MTVA) will present DA-1726 Phase 1 clinical trial data at the Precision Liver Symposium on November 4, 2026.The accepted oral presentation concerns a randomized, placebo-controlled trial. Its title describes reductions in liver fat measured by MRI-PDFF, an imaging-based measure, and weight loss with relative preservation of lean mass. DA-1726 is a drug candidate targeting both GLP-1 and glucagon receptors.Chief Medical Officer Sarah Browne, M.D., will deliver the presentation at 1:35 pm MT at the Hilton Denver City Center in Denver, Colorado. A copy of the poster will be available in the Posters section of MetaVia’s website after the presentation. The announcement provides no numerical trial results for the presentation.
www.stocktitan.net
October 28, 2026 at 12:31 PM
#MTVA MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
https://www.stocktitan.net/news/MTVA/meta-via-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-mtlixf7tl5hr.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-mtlixf7tl5hr.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $MTVA
On October 28, 2026, MetaVia Inc. issued a press release announcinghat an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation a...
On October 28, 2026, MetaVia Inc. issued a press release announcinghat an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation a...
SEC Filing: MTVA
Click to view the official SEC document.
www.sec.gov
October 28, 2026 at 1:01 PM
🚨 $MTVA
On October 28, 2026, MetaVia Inc. issued a press release announcinghat an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation a...
On October 28, 2026, MetaVia Inc. issued a press release announcinghat an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation a...
🧬 MetaVia appointed Sarah Browne as Chief Medical Officer.
⚖️ NeuroSense secured a Nasdaq hearing date for PrimeC.
📊 Goldman Sachs reported its Q3 FY26 earnings results.
💵 Citigroup Q3 profit climbed on 8% revenue growth.
⚖️ NeuroSense secured a Nasdaq hearing date for PrimeC.
📊 Goldman Sachs reported its Q3 FY26 earnings results.
💵 Citigroup Q3 profit climbed on 8% revenue growth.
October 13, 2026 at 7:12 PM
🧬 MetaVia appointed Sarah Browne as Chief Medical Officer.
⚖️ NeuroSense secured a Nasdaq hearing date for PrimeC.
📊 Goldman Sachs reported its Q3 FY26 earnings results.
💵 Citigroup Q3 profit climbed on 8% revenue growth.
⚖️ NeuroSense secured a Nasdaq hearing date for PrimeC.
📊 Goldman Sachs reported its Q3 FY26 earnings results.
💵 Citigroup Q3 profit climbed on 8% revenue growth.
#MTVA MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
https://www.stocktitan.net/news/MTVA/meta-via-appoints-seasoned-clinical-development-executive-sarah-21hbrx7ef9ud.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-appoints-seasoned-clinical-development-executive-sarah-21hbrx7ef9ud.html?utm_source=stocktitan-bluesky&utm_medium=social
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 13, 2026 at 12:31 PM
#MTVA MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
https://www.stocktitan.net/news/MTVA/meta-via-appoints-seasoned-clinical-development-executive-sarah-21hbrx7ef9ud.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-appoints-seasoned-clinical-development-executive-sarah-21hbrx7ef9ud.html?utm_source=stocktitan-bluesky&utm_medium=social
🚨 $MTVA
On October 13, 2026, MetaVia Inc. issued a press release announcing the appointment of Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective as of October 12, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herei...
On October 13, 2026, MetaVia Inc. issued a press release announcing the appointment of Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective as of October 12, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herei...
SEC Filing: MTVA
Click to view the official SEC document.
www.sec.gov
October 13, 2026 at 12:35 PM
🚨 $MTVA
On October 13, 2026, MetaVia Inc. issued a press release announcing the appointment of Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective as of October 12, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herei...
On October 13, 2026, MetaVia Inc. issued a press release announcing the appointment of Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective as of October 12, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herei...
Latest company news, September 9: MetaVia reported preclinical findings on DA-1726 supporting its waist circumference reduction.
MetaVia (#$MTVA): Can Longer DA-1726 Data Support the Next Step?
www.merlintrader.com/metavia-inc-...
MetaVia (#$MTVA): Can Longer DA-1726 Data Support the Next Step?
www.merlintrader.com/metavia-inc-...
MetaVia ($MTVA): DA-1726 Data And Funding
MetaVia faces longer DA-1726 obesity results, a limited cash horizon and material warrants. Dated clinical evidence, financing conditions and risks for $MTVA.
www.merlintrader.com
October 7, 2026 at 2:48 PM
Latest company news, September 9: MetaVia reported preclinical findings on DA-1726 supporting its waist circumference reduction.
MetaVia (#$MTVA): Can Longer DA-1726 Data Support the Next Step?
www.merlintrader.com/metavia-inc-...
MetaVia (#$MTVA): Can Longer DA-1726 Data Support the Next Step?
www.merlintrader.com/metavia-inc-...
MetaVia (#$MTVA): DA-1726 16-Week Data Expected in Q4 2026
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/metavia-inc-...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/metavia-inc-...
September 24, 2026 at 9:37 AM
MetaVia (#$MTVA): DA-1726 16-Week Data Expected in Q4 2026
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/metavia-inc-...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/metavia-inc-...
🚀 Zacks Small Cap Research - MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-mtva-preclinical-findings-support-da-1726-waist-circumference-reduction/
#ZacksSCR #ZacksSCRt#MTVA##MetaViaW#DA1726ref="/hashtag/Wais" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Wais
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-mtva-preclinical-findings-support-da-1726-waist-circumference-reduction/
#ZacksSCR #ZacksSCRt#MTVA##MetaViaW#DA1726ref="/hashtag/Wais" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Wais
September 10, 2026 at 4:57 PM
🚀 Zacks Small Cap Research - MTVA: Preclinical Findings Support DA-1726 Waist Circumference Reduction
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-mtva-preclinical-findings-support-da-1726-waist-circumference-reduction/
#ZacksSCR #ZacksSCRt#MTVA##MetaViaW#DA1726ref="/hashtag/Wais" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Wais
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-mtva-preclinical-findings-support-da-1726-waist-circumference-reduction/
#ZacksSCR #ZacksSCRt#MTVA##MetaViaW#DA1726ref="/hashtag/Wais" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Wais
MetaVia Inc. Presents Groundbreaking Preclinical Study on DA-1726's Effectiveness in Waist Size Reduction#USA#Cambridge#obesity#MetaVia#DA-1726
MetaVia Inc. Presents Groundbreaking Preclinical Study on DA-1726's Effectiveness in Waist Size Reduction
MetaVia Inc. unveils significant preclinical findings supporting DA-1726's potential for reducing waist circumference, a promising step in obesity treatment.
third-news.com
September 9, 2026 at 12:25 PM
MetaVia Inc. Presents Groundbreaking Preclinical Study on DA-1726's Effectiveness in Waist Size Reduction#USA#Cambridge#obesity#MetaVia#DA-1726
$MTVA — Press Release
MetaVia Inc. announced preclinical results for its DA-1726 candidate, showing that the drug-derived radioactivity is slowly absorbed and extensively distributed throughout the body after subcutaneous injection, with the highest exposure in adipose (fat) tissue.
🧵 continued ↓
MetaVia Inc. announced preclinical results for its DA-1726 candidate, showing that the drug-derived radioactivity is slowly absorbed and extensively distributed throughout the body after subcutaneous injection, with the highest exposure in adipose (fat) tissue.
🧵 continued ↓
September 9, 2026 at 4:47 PM
$MTVA — Press Release
MetaVia Inc. announced preclinical results for its DA-1726 candidate, showing that the drug-derived radioactivity is slowly absorbed and extensively distributed throughout the body after subcutaneous injection, with the highest exposure in adipose (fat) tissue.
🧵 continued ↓
MetaVia Inc. announced preclinical results for its DA-1726 candidate, showing that the drug-derived radioactivity is slowly absorbed and extensively distributed throughout the body after subcutaneous injection, with the highest exposure in adipose (fat) tissue.
🧵 continued ↓
#MTVA MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
https://www.stocktitan.net/news/MTVA/meta-via-announces-preclinical-findings-supporting-biological-zykxbt2riofi.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-announces-preclinical-findings-supporting-biological-zykxbt2riofi.html?utm_source=stocktitan-bluesky&utm_medium=social
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 9, 2026 at 12:00 PM
#MTVA MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
https://www.stocktitan.net/news/MTVA/meta-via-announces-preclinical-findings-supporting-biological-zykxbt2riofi.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/MTVA/meta-via-announces-preclinical-findings-supporting-biological-zykxbt2riofi.html?utm_source=stocktitan-bluesky&utm_medium=social